Stock Events

Cartesian Therapeutics 

€0.65
3
-€0.01-0.92% Monday 15:19

Statistics

Day High
0.66
Day Low
0.65
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
164.43M
P/E Ratio
3.98
Dividend Yield
-
Dividend
-

Earnings

1NovExpected
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
-0.14
-0.02
0.11
0.23
Expected EPS
-0.1097
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1S7.F. It's not an investment recommendation.

About

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising SEL-313, a product candidate in preclinical stage to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to evaluate the appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and products for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat primary biliary cholangitis and other autoimmune diseases. The company has license and collaboration agreements with Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum; Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Ginkgo Bioworks Holdings, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
Show more...
CEO
Dr. Carsten Brunn Ph.D.
Employees
58
Country
US
ISIN
US8162121045
WKN
000A2AML0

Listings